Abstract
Adverse outcome pathways are tools to capture and visualize mechanisms underlying adverse effects, and are currently emerging in the areas of toxicology and chemical risk assessment. Less attention has yet been paid to potential clinical applications of adverse outcome pathways, including in the hepatology field. Liver adverse outcome pathways can serve the development and optimization of the clinically relevant animal models of liver diseases for fundamental and translational research as well as for testing new liver therapeutics. They also can aid the characterization of novel and more specific diagnostic and prognostic biomarkers of liver disease. Full clinical exploitation in these directions requires further technical optimization of adverse outcome pathways as well as intensive interdisciplinary and intersectoral collaboration.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of gastrointestinal and liver diseases : JGLD
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
